Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Pain & anesthesia · 2025

Journavx (suzetrigine)

The FDA approved Journavx (suzetrigine) on January 30, 2025 to treat moderate to severe acute pain.
Brand name
Journavx
Generic name
suzetrigine
FDA approval date
January 30, 2025
Approved use (FDA wording)
To treat moderate to severe acute pain
Drug class (EPC)
Sodium Channel Blocker [EPC]
Boxed warning on label
Not listed
Category on this site
Pain & anesthesia

Indications and usage, from the FDA label

JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.